MGF (Mechano Growth Factor)

Muscle / Recovery

Also known as: Mechano Growth Factor, IGF-1Ec, PEG-MGF

Insulin-Like Growth FactorsResearch phase: Preclinical, limited human observational dataRegulatory: Not FDA-approved. Research chemical.

Mechanism

A splice variant of IGF-1 that's specifically produced when muscles are damaged from exercise. It activates dormant muscle stem cells (satellite cells) to repair and grow new muscle tissue. It's like the body's natural muscle-repair signal, concentrated into an injectable form.

Technical detail

Splice variant of IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents). Produced locally in skeletal muscle in response to mechanical strain/damage. Contains unique 24-amino acid C-terminal E-domain that distinguishes it from systemic IGF-1Ea. Activates quiescent satellite cells, promoting their proliferation (but not differentiation — that's IGF-1Ea's role). PEG-MGF: pegylated form extends half-life from minutes to hours. Published in Journal of Physiology (Goldspink, 2005). Declines significantly with age (contributing to sarcopenia).

Effects

## MGF (Mechano Growth Factor) — System-by-System Effects ### Musculoskeletal System (Primary) - **Splice variant of IGF-1**: MGF is a splice variant of the IGF-1 gene (IGF-1Ec in humans). It is produced locally in muscle tissue in response to mechanical stress (exercise, stretching, damage). It is NOT the same as systemic IGF-1 or IGF-1 LR3. [Tier 1 — established molecular biology] - **Satellite cell activation**: MGF's primary function is activating muscle satellite cells (muscle stem cells) at the site of mechanical damage. This is the initial repair/growth signal before systemic IGF-1 takes over. [Tier 1] - **Local vs. systemic**: MGF is designed by nature to be a LOCAL, SHORT-LIVED signal. It has a very short half-life in circulation (~minutes). This is fundamentally different from IGF-1 LR3 (hours). MGF is the "first responder"; IGF-1 is the "sustained support." [Tier 1] - **Muscle repair**: Promotes muscle fiber repair after damage. Critical for the eccentric exercise → damage → repair → growth cycle. [Tier 1] - **Hypertrophy**: Through satellite cell activation and fusion, MGF contributes to muscle fiber hypertrophy and potentially hyperplasia. [Tier 2] ### Modified MGF (PEG-MGF) - **Pegylated version**: PEG-MGF has a polyethylene glycol molecule attached, dramatically extending its half-life from minutes to hours. This is the form commonly sold in the peptide community. [Tier 2] - **Altered biology**: By extending the half-life, PEG-MGF changes the fundamental biology — from a local, pulsatile signal to a systemic, sustained one. Whether this is beneficial or counterproductive is genuinely unknown. [Tier 3] ### Connective Tissue - **Tendon and ligament repair**: Some evidence that MGF supports connective tissue repair, not just muscle. [Tier 2-3] - **Bone healing**: IGF-1 variants including MGF may support fracture healing. [Tier 2-3] ### Cardiac - **Cardiac repair**: MGF is expressed in cardiac tissue after ischemic injury. May promote cardiomyocyte survival and repair. [Tier 2]

Practitioner Guide

## MGF (Mechano Growth Factor) — Practitioner Guide ### Clinical Profile MGF is a naturally occurring splice variant of IGF-1, produced locally in muscle after mechanical stress. The synthetic version (and especially PEG-MGF) is used in the performance community for muscle growth and recovery. Understanding its biology helps distinguish it from IGF-1 LR3 and informs realistic expectations. ### MGF vs. IGF-1 LR3 — Critical Distinctions | Feature | MGF (natural) | PEG-MGF | IGF-1 LR3 | |---------|---------------|---------|-----------| | Half-life | Minutes | Hours | 20-30 hours | | Action | Local, pulsatile | Systemic (altered) | Systemic | | Primary effect | Satellite cell activation | Unknown (altered biology) | mTOR/protein synthesis | | Cancer concern | Low (local, brief) | Moderate | High | | Hypoglycemia risk | Low | Low-moderate | Moderate-high | ### Community Protocols - **PEG-MGF dose**: 200-400mcg per injection, typically bilateral (e.g., 200mcg into each quad after leg training) - **Timing**: Immediately post-workout into the trained muscle group (biological rationale: mimicking natural MGF expression) - **Frequency**: Training days only, into trained muscle groups - **Duration**: 4-8 weeks - **Non-pegylated MGF**: Rarely used due to extremely short half-life making effective dosing impractical ### Realistic Expectations - **Even less dramatic than IGF-1 LR3**: Most users report modest recovery improvement rather than significant hypertrophy - **The "feel" benefit**: Many users report trained muscles feel "fuller" and recover faster between sessions. Whether this translates to measurable mass gain is debatable. - **Local injection rationale**: Unlike LR3, there is actual biological rationale for site-specific MGF injection — natural MGF IS a local signal. However, PEG-MGF's extended half-life undermines this rationale somewhat. - **Stacking**: Often used alongside IGF-1 LR3 or GH in more advanced protocols. MGF post-workout for satellite cell activation, LR3 on rest days for sustained anabolic signaling. This is theoretically logical but completely unstudied. ### Practitioner Perspective - MGF is conceptually interesting but practically limited - The evidence for exogenous MGF injection producing meaningful muscle growth in humans does not exist - PEG-MGF fundamentally alters the biology of a naturally local, pulsatile signal — the consequences are unknown - If patients want growth factor-based muscle enhancement, GH peptides (CJC-1295/Ipamorelin) have better safety data and more predictable results - The strongest argument for MGF is recovery support for serious athletes, not mass building ### Safety Profile - Better theoretical safety than IGF-1 LR3 (less systemic, less insulin-like) - PEG-MGF's extended half-life makes it more similar to LR3 in risk profile - No controlled safety data for any form - Cancer risk is theoretically lower than LR3 but unstudied - Hypoglycemia risk is lower than LR3 - The biggest risk may be wasted money on products of uncertain quality

Dosing Protocols

muscle_recoverybasic tier
Dose
100mcg
Frequency
2-3x per week, post-workout only
Timing
Immediately post-workout, inject into the target muscle that was trained
Route
intramuscular
Cycle
4-6 weeks

PEG-MGF is the PEGylated form of Mechano Growth Factor (MGF), a splice variant of IGF-1 (IGF-1Ec) produced by mechanically stressed muscle tissue. The PEG modification extends half-life from minutes to several hours. Inject directly into trained muscle immediately post-workout to activate satellite cells and promote muscle fiber repair. Local IM injection concentrates the peptide at the site of mechanical damage for targeted recovery.

muscle_recoveryintermediate tier
Dose
200mcg
Frequency
2-3x per week, post-workout only
Timing
Immediately post-workout, split dose between 2 target muscles if multiple groups trained (e.g., 100mcg per muscle)
Route
intramuscular
Cycle
4-6 weeks

Higher dose for experienced users. PEG-MGF activates satellite cells in a mechano-sensitive manner, meaning it is most effective when injected into mechanically damaged tissue. At 200mcg per session, split between trained muscles for broader recovery. Do not use on rest days — MGF signaling is dependent on prior mechanical tension. PEGylation prevents rapid degradation but the peptide remains most active in the 4-6 hours post-injection.

Contraindications & Cautions

  • hard stop — Active cancer
    MGF is an IGF-1 splice variant that promotes cell proliferation and satellite cell activation. Like other IGF-1 family members, it has mitogenic properties that may accelerate tumor growth and progression.
    Action: Do not use in patients with any active cancer.
  • hard stop — Pregnancy
    No human safety data. Growth factor with proliferative activity poses risk to fetal development.
    Action: Do not use during pregnancy.
  • hard stop — Breastfeeding
    No data on safety during lactation.
    Action: Do not use while breastfeeding.
  • hard stop — Under 18 years of age
    Growth factor peptide. Not for pediatric use.
    Action: Do not provide to individuals under 18.
  • requires physician — Diabetes
    As an IGF-1 splice variant, MGF may have glucose-lowering effects and interact with insulin signaling. Limited clinical data on glycemic impact.
    Action: Requires physician supervision. Monitor blood glucose.

Evidence

  • Gene expression in skeletal muscle in response to stretch and force generation

    Goldspink G (2003) — American Journal of Physiology — PMID: 12388137

    Mechano Growth Factor (MGF), a splice variant of IGF-1 (IGF-1Ec in humans), is expressed locally in muscle tissue in response to mechanical stretch and damage. MGF activates satellite cells (muscle stem cells) and initiates muscle repair and hypertrophy. Expression declines with age, potentially contributing to sarcopenia. Distinct from systemic IGF-1Ea in its autocrine/paracrine signaling role.

    emerging

Stacks featuring this peptide

The Muscle Builder Stack
Muscle Growth / Performance · advanced

The most aggressive peptide-based muscle growth stack. MK-677 (oral) provides 24-hour sustained GH and IGF-1 elevation as the hormonal foundation. IGF-1 LR3 (injectable) adds direct IGF-1 receptor activation with 100-fold less IGFBP binding than native IGF-1, promoting both hypertrophy (existing muscle fibers grow) and hyperplasia (new muscle fiber formation via satellite cell recruitment). PEG-MGF is injected post-workout into target muscles to activate dormant satellite cells — these are the stem cells that fuse with existing fibers to create new myonuclei (permanent gains). Follistatin 344 removes the myostatin brake that limits how much muscle your body allows you to build. Four synergistic pathways: sustained GH (MK-677), direct IGF-1 receptor agonism (LR3), satellite cell activation (MGF), and myostatin blockade (Follistatin).

Research Summary

## MGF — Research Summary ### Tier 1 (Strong Clinical Evidence) - **MGF biology**: MGF as a splice variant of IGF-1, expressed locally in muscle after mechanical stress, is well-characterized (Goldspink et al., multiple publications). The molecular biology is solid. - **Satellite cell activation**: MGF's role in activating muscle satellite cells is established through cell culture and animal studies. - **Local vs. systemic IGF-1 action**: The concept of local (MGF) vs. systemic (hepatic IGF-1) growth factor action in muscle is well-supported. ### Tier 2 (Moderate Evidence) - **PEG-MGF pharmacology**: Pegylation extends half-life, but the biological consequences of this alteration are not well-studied. - **Cardiac MGF**: Expression of MGF in cardiac tissue after injury documented. Therapeutic potential for cardiac repair is preclinical. - **Connective tissue effects**: Some preclinical evidence for MGF supporting tendon and bone repair. ### Tier 3 (Emerging/Anecdotal) - **Exogenous MGF for muscle growth**: Zero controlled human studies. Community reports are largely anecdotal with modest positive claims. - **PEG-MGF altered biology**: The consequences of changing MGF from a local, pulsatile signal to a systemic, sustained one are completely unknown. - **Product quality**: Like other complex peptides, commercial MGF/PEG-MGF quality is variable and largely untested. ### Key Research Gaps - No human studies of exogenous MGF or PEG-MGF for any indication - Whether PEG-MGF retains the satellite cell activation function of natural MGF - Whether site-specific injection of PEG-MGF produces local effects - Safety of repeated exogenous MGF/PEG-MGF administration - Comparison with other recovery/growth interventions

Build a personalized protocol with MGF (Mechano Growth Factor) →